BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33653799)

  • 21. Tissue-resident memory-like T cells in tumor immunity: Clinical implications.
    Dhodapkar MV; Dhodapkar KM
    Semin Immunol; 2020 Jun; 49():101415. PubMed ID: 33011063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy.
    Binnewies M; Pollack JL; Rudolph J; Dash S; Abushawish M; Lee T; Jahchan NS; Canaday P; Lu E; Norng M; Mankikar S; Liu VM; Du X; Chen A; Mehta R; Palmer R; Juric V; Liang L; Baker KP; Reyno L; Krummel MF; Streuli M; Sriram V
    Cell Rep; 2021 Oct; 37(3):109844. PubMed ID: 34686340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
    Steggerda SM; Bennett MK; Chen J; Emberley E; Huang T; Janes JR; Li W; MacKinnon AL; Makkouk A; Marguier G; Murray PJ; Neou S; Pan A; Parlati F; Rodriguez MLM; Van de Velde LA; Wang T; Works M; Zhang J; Zhang W; Gross MI
    J Immunother Cancer; 2017 Dec; 5(1):101. PubMed ID: 29254508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors.
    Romagnani A; Rottoli E; Mazza EMC; Rezzonico-Jost T; De Ponte Conti B; Proietti M; Perotti M; Civanelli E; Perruzza L; Catapano AL; Baragetti A; Tenedini E; Tagliafico E; Falzoni S; Di Virgilio F; Norata GD; Bicciato S; Grassi F
    Cancer Res; 2020 Sep; 80(18):3906-3919. PubMed ID: 32699136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.
    Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M
    Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991
    [No Abstract]   [Full Text] [Related]  

  • 28. Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8
    Mastelic-Gavillet B; Navarro Rodrigo B; Décombaz L; Wang H; Ercolano G; Ahmed R; Lozano LE; Ianaro A; Derré L; Valerio M; Tawadros T; Jichlinski P; Nguyen-Ngoc T; Speiser DE; Verdeil G; Gestermann N; Dormond O; Kandalaft L; Coukos G; Jandus C; Ménétrier-Caux C; Caux C; Ho PC; Romero P; Harari A; Vigano S
    J Immunother Cancer; 2019 Oct; 7(1):257. PubMed ID: 31601268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy.
    Qiu H; Shao Z; Wen X; Jiang J; Ma Q; Wang Y; Huang L; Ding X; Zhang L
    Front Immunol; 2021; 12():716710. PubMed ID: 34539652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA-G/LILRBs: A Cancer Immunotherapy Challenge.
    Carosella ED; Gregori S; Tronik-Le Roux D
    Trends Cancer; 2021 May; 7(5):389-392. PubMed ID: 33563576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
    Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
    Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.
    Wang Y; Sun SN; Liu Q; Yu YY; Guo J; Wang K; Xing BC; Zheng QF; Campa MJ; Patz EF; Li SY; He YW
    Cancer Discov; 2016 Sep; 6(9):1022-35. PubMed ID: 27297552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-expression of immunoglobulin-like transcript 4 and angiopoietin-like proteins in human non-small cell lung cancer.
    Wang L; Geng T; Guo X; Liu J; Zhang P; Yang D; Li J; Yu S; Sun Y
    Mol Med Rep; 2015 Apr; 11(4):2789-96. PubMed ID: 25482926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.
    Zhou Q; Xiao H; Liu Y; Peng Y; Hong Y; Yagita H; Chandler P; Munn DH; Mellor A; Fu N; He Y
    J Immunol; 2010 Nov; 185(9):5082-92. PubMed ID: 20926790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rescuing lymphocytes from HLA-G immunosuppressive effects mediated by the tumor microenvironment.
    Wu D; Kuiaste I; Moreau P; Carosella E; Yotnda P
    Oncotarget; 2015 Nov; 6(35):37385-97. PubMed ID: 26460949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
    Kumar A; Chamoto K; Chowdhury PS; Honjo T
    Elife; 2020 Mar; 9():. PubMed ID: 32122466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
    Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
    J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remodeling of the tumor microenvironment via disrupting Blimp1
    Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
    Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.